Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Current Assets (2020 - 2026)

Nautilus Biotechnology has reported Current Assets over the past 7 years, most recently at $98.8 million for Q1 2026.

  • Quarterly results put Current Assets at $98.8 million for Q1 2026, down 30.2% from a year ago — trailing twelve months through Mar 2026 was $98.8 million (down 30.2% YoY), and the annual figure for FY2025 was $106.0 million, down 20.22%.
  • Current Assets reached $98.8 million in Q1 2026 per NAUT's latest filing, down from $106.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $327.1 million in Q1 2022 and bottomed at $98.8 million in Q1 2026.
  • Median Current Assets over the past 5 years was $170.5 million (2023), compared with a mean of $179.1 million.
  • The largest annual shift saw Current Assets surged 34856.29% in 2022 before it crashed 47.87% in 2023.
  • Over 5 years, Current Assets stood at $187.2 million in 2022, then decreased by 5.54% to $176.8 million in 2023, then fell by 24.89% to $132.8 million in 2024, then dropped by 20.22% to $106.0 million in 2025, then fell by 6.73% to $98.8 million in 2026.
  • Business Quant data shows Current Assets for NAUT at $98.8 million in Q1 2026, $106.0 million in Q4 2025, and $134.3 million in Q3 2025.